Analgesic Additives to Epidural Bupivacaine in Normal Labor

• Status: Not yet recruiting
• Trial end date: 2025-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the study will be to compare the role of Dexmedetomidine, Nalbuphine and fentanyl as additives to epidural bupivacaine in painless vaginal delivery as regard of effectiveness analgesia and maternal safety.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assiut University
• Treatments: Dexmedetomidine; Fentanyl; Nalbuphine

Criteria

Inclusion Criteria:

• >/= 18 years of age

• American Society of Anesthesiologists (ASA) Physical Status 2 or 3

• Full term pregnancy (>37 gestational weeks)

• Planning vaginal delivery

• Planning epidural labor analgesia

• Vertex presentation

Exclusion Criteria:

• Patient refusal to epidural analgesia,

• Contraindications of epidural analgesia (coagulopathy, local infection, vertebral deformity)

• Allergy to study agents (hypersensitivity to bupivacaine, Nalbuphine, fentanyl or dexmedetomidine)

• hemodynamic instability, severe aortic or mitral stenosis)

• Severe pre-eclampsia,

• Breech presentations

• Antepartum hemorrhage

• Cephalopelvic disproportion

• Body mass index ≥40 kg/m2.

• Uncontrolled systemic comorbidities [i.e., diabetes, hepatic, renal or cardiac]

• Known or suspected fetal abnormalities

• Inability to communicate or participate in study procedures